IDEAYA Biosciences Darovasertib Combo Advances Uveal Melanoma Care

South San Francisco, California, USA, April 21, 2026

In a significant advancement in precision oncology, IDEAYA Biosciences, Inc. has announced a late-breaking oral presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, where it will unveil complete data from its Phase 2/3 registrational trial (OptimUM-02) evaluating darovasertib in combination with crizotinib for first-line treatment of HLA-A2-negative metastatic uveal melanoma. This milestone highlights the company’s commitment to developing targeted therapies tailored to genetically defined cancers, addressing a critical unmet need in a rare and aggressive form of melanoma. The presentation is expected to include comprehensive clinical outcomes beyond previously released topline data, offering deeper insights into the therapy’s efficacy, safety, and potential to redefine treatment standards in this underserved patient population.

Darovasertib Combination Targets Rare Aggressive Cancer

The darovasertib plus crizotinib combination represents a novel therapeutic approach designed to improve outcomes in patients with metastatic uveal melanoma, particularly those who are HLA-A2-negative, a subgroup with limited treatment options and poor prognosis. Uveal melanoma is a rare but highly aggressive cancer originating in the eye, often progressing to metastatic disease with limited survival rates.

The OptimUM-02 trial evaluates this combination as a first-line treatment, comparing it against investigator’s choice therapies, thereby aiming to establish a new standard of care. Darovasertib, a protein kinase C (PKC) inhibitor, works by targeting key signaling pathways involved in tumor growth, while crizotinib, a MET inhibitor, complements this mechanism to enhance anti-tumor activity. Together, this dual-targeted strategy is designed to deliver more durable responses and improved progression-free survival in patients who currently face limited therapeutic options.

Late-Breaking ASCO Presentation Highlights Clinical Impact

Being selected for a late-breaking abstract (LBA) oral presentation at ASCO 2026 is a strong indicator of the clinical significance and potential impact of the OptimUM-02 trial results. Late-breaking sessions typically feature high-impact data that could influence clinical practice, underscoring the importance of IDEAYA’s findings in the oncology community. The presentation, scheduled for June 1, 2026, will provide detailed efficacy and safety data, including outcomes not previously disclosed in initial announcements.

This visibility at ASCO positions IDEAYA at the forefront of innovation in melanoma treatment, particularly in the context of biomarker-driven precision medicine. The company’s integrated approach—leveraging structural biology, bioinformatics, and translational biomarkers—enables the development of therapies that are highly selective and aligned with the genetic drivers of disease, increasing the likelihood of clinical success.

Strategic Advancement in Precision Oncology Pipeline

The OptimUM-02 trial represents a cornerstone in IDEAYA’s broader strategy to build a robust pipeline of first-in-class and best-in-class targeted therapies. By focusing on synthetic lethality and molecularly defined tumor indications, the company aims to deliver therapies that are not only more effective but also personalized to individual patient profiles. The success of darovasertib in combination with crizotinib could significantly enhance IDEAYA’s position in the competitive oncology landscape, particularly in rare cancers where innovation is urgently needed.

Furthermore, positive results from this registrational trial could support future regulatory submissions and commercialization efforts, potentially bringing a new treatment option to market for patients with metastatic uveal melanoma. As the oncology field continues to shift toward precision medicine, IDEAYA’s approach exemplifies the next generation of targeted cancer therapies designed to overcome limitations of traditional treatments and deliver meaningful clinical benefit.

Overall, IDEAYA Biosciences’ upcoming ASCO presentation marks a pivotal moment in the development of darovasertib-based combination therapy, with the potential to transform treatment paradigms for rare and genetically defined cancers. By advancing innovative, biomarker-driven therapies, the company is contributing to the evolution of oncology toward more precise, effective, and patient-centric care.

Source: IDEAYA Biosciences press release